[go: up one dir, main page]

WO2016125190A3 - Nouvelles formes cristallines de vortioxétine, prémélanges, et procédés pour la préparation de ceux-ci - Google Patents

Nouvelles formes cristallines de vortioxétine, prémélanges, et procédés pour la préparation de ceux-ci Download PDF

Info

Publication number
WO2016125190A3
WO2016125190A3 PCT/IN2016/050041 IN2016050041W WO2016125190A3 WO 2016125190 A3 WO2016125190 A3 WO 2016125190A3 IN 2016050041 W IN2016050041 W IN 2016050041W WO 2016125190 A3 WO2016125190 A3 WO 2016125190A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
vortioxetine
crystalline forms
premixes
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2016/050041
Other languages
English (en)
Other versions
WO2016125190A2 (fr
Inventor
Ramakoteswara Rao Jetti
Asharani GORANTLA
Satish BEERAVALLI
Sureshbabu JAYACHANDRA
Rathinapandian JEBARAJ
Anjaneyaraju Indukuri
Bommareddy AGGIRAMIREDDY
Amit Singh
Soumyajit GHOSH
Attanti Veera Venkata SRINIVASARAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of WO2016125190A2 publication Critical patent/WO2016125190A2/fr
Publication of WO2016125190A3 publication Critical patent/WO2016125190A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formes cristallines de bromhydrate de vortioxétine, désignées comme forme-M1, forme-M2, forme-M3, et forme-M4. La présente invention concerne également un prémélange pharmaceutique d'une forme-M2 cristalline de bromhydrate de vortioxétine et d'excipients pharmaceutiquement acceptables et un procédé de préparation associé, ainsi qu'un prémélange pharmaceutique de bromhydrate de vortioxétine amorphe et d'excipients pharmaceutiquement acceptables et un procédé de préparation associé. Dans certains modes de réalisation, la génération d'un prémélange qui comprend du bromhydrate de vortioxétine amorphe et de la β-cyclodextrine s'est avérée particulièrement stable et avantageuse.
PCT/IN2016/050041 2015-02-04 2016-02-04 Nouvelles formes cristallines de vortioxétine, prémélanges, et procédés pour la préparation de ceux-ci Ceased WO2016125190A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN551CH2015 2015-02-04
IN551/CHE/2015 2015-02-04
IN2301/CHE/2015 2015-05-05
IN2301CH2015 2015-05-05
IN5243CH2015 2015-09-30
IN5243/CHE/2015 2015-09-30

Publications (2)

Publication Number Publication Date
WO2016125190A2 WO2016125190A2 (fr) 2016-08-11
WO2016125190A3 true WO2016125190A3 (fr) 2016-09-29

Family

ID=55802406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2016/050041 Ceased WO2016125190A2 (fr) 2015-02-04 2016-02-04 Nouvelles formes cristallines de vortioxétine, prémélanges, et procédés pour la préparation de ceux-ci

Country Status (1)

Country Link
WO (1) WO2016125190A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2015633A3 (cs) * 2015-09-16 2017-03-29 Zentiva, K.S. Amorfní forma vortioxetin hydrobromidu stabilizovaná cyklodextrinem
WO2017125504A1 (fr) * 2016-01-20 2017-07-27 Amneal Pharmaceuticals Company Gmbh Formes polymorphes de tert-butanolate de bromhydrate de vortioxétine
US20190224192A1 (en) * 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
US10836730B2 (en) * 2017-02-23 2020-11-17 Unichem Laboratories Ltd. Process for preparation and purification of vortioxetine hydrobromide
CN110372635B (zh) * 2018-04-12 2021-06-04 浙江京新药业股份有限公司 氢溴酸沃替西汀α晶型的制备方法
CN111330018B (zh) * 2018-12-18 2023-07-21 浙江京新药业股份有限公司 沃替西汀-环糊精包合物、制备方法及其药物组合物
CN115160258B (zh) * 2022-06-24 2023-11-17 辰欣药业股份有限公司 一种氢溴酸沃替西汀γ晶型的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144005A1 (fr) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1-[2-(2, 4-diméthylphénylsulfanyl)-phényl]pipérazine comme composé présentant une activité sur la sérotonine, 5-ht3 et 5-ht1a pour le traitement du déficit cognitif
WO2014044721A1 (fr) * 2012-09-19 2014-03-27 Sandoz Ag Nouvelle forme cristalline de bromhydrate de vortioxétine
WO2014177491A1 (fr) * 2013-04-29 2014-11-06 Lek Pharmaceuticals D.D. Nouvelle forme solide de bromhydrate de 1-(2-((2,4-diméthylphényl)thio)phényl)pipérazine
WO2015044963A1 (fr) * 2013-09-30 2015-04-02 Cadila Healthcare Limited Vortioxétine amorphe et sels de ladite substance
WO2016062860A1 (fr) * 2014-10-24 2016-04-28 H E X A L Aktiengesellschaft Bromhydrate de vortioxétine amorphe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
CA2759456C (fr) 2009-04-24 2017-10-31 H. Lundbeck A/S Formulations liquides de sels de 1-[2-(2,4-dimethylphenylsulfanyl)- phenyl]piperazine
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144005A1 (fr) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1-[2-(2, 4-diméthylphénylsulfanyl)-phényl]pipérazine comme composé présentant une activité sur la sérotonine, 5-ht3 et 5-ht1a pour le traitement du déficit cognitif
WO2014044721A1 (fr) * 2012-09-19 2014-03-27 Sandoz Ag Nouvelle forme cristalline de bromhydrate de vortioxétine
WO2014177491A1 (fr) * 2013-04-29 2014-11-06 Lek Pharmaceuticals D.D. Nouvelle forme solide de bromhydrate de 1-(2-((2,4-diméthylphényl)thio)phényl)pipérazine
WO2015044963A1 (fr) * 2013-09-30 2015-04-02 Cadila Healthcare Limited Vortioxétine amorphe et sels de ladite substance
WO2016062860A1 (fr) * 2014-10-24 2016-04-28 H E X A L Aktiengesellschaft Bromhydrate de vortioxétine amorphe

Also Published As

Publication number Publication date
WO2016125190A2 (fr) 2016-08-11

Similar Documents

Publication Publication Date Title
WO2016125190A3 (fr) Nouvelles formes cristallines de vortioxétine, prémélanges, et procédés pour la préparation de ceux-ci
WO2015166379A3 (fr) Nouvelles formes polymorphes de la vortioxétine et de ses sels pharmaceutiquement acceptables
WO2016131067A3 (fr) Compositions pharmaceutiques contenant du méloxicam
WO2016014927A3 (fr) Forme cristalline du riboside de nicotinamide
WO2016044556A3 (fr) Inhibiteurs d'arginine méthyltransférase et leurs utilisations
HK1231471A1 (zh) 6-杂芳氧基-和6芳氧基-喹啉-2-甲酰胺及其用途
WO2015110897A3 (fr) Nouveau procédé de préparation de dolutégravir et de ses sels pharmaceutiquement acceptables
WO2016079751A3 (fr) Procédé de préparation de vortioxétine et de polymorphes de cette substance
WO2016016766A3 (fr) Procédé de préparation d'isavuconazonium ou de son sel
WO2015019198A3 (fr) Compositions pharmaceutiques de pancréatine de puissance élevée
WO2016125191A3 (fr) Procédés de préparation de bromhydrate de vortioxétine
MX382600B (es) Forma cristalina de base libre de lorlatinib.
FI3800177T3 (fi) Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
WO2016038542A3 (fr) Formes polymorphes de sofosbuvir
WO2016125192A3 (fr) Procédé de préparation de dolutégravir
ZA202407964B (en) Processes for preparing ag-10, its intermediates, and salts thereof
IN2013MU00711A (fr)
WO2019203771A3 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
WO2015068175A3 (fr) Procédé perfectionné de préparation de pazopanib ou d'un sel de qualité pharmaceutique de celui-ci
IN2013MU01985A (fr)
WO2016149631A3 (fr) Production acellulaire de butanol
WO2015002755A3 (fr) Composés pour le traitement du paludisme
WO2014006636A3 (fr) Compositions stables de fésotérodine
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16717713

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16717713

Country of ref document: EP

Kind code of ref document: A2